GlaxoSmithKline announced on May 20 that it will support developing countries that have growing economies by putting a five year freeze on vaccine prices for countries who graduate from GAVI Alliance support.
The announcement was made by Andrew Witty, the CEO of GSK, at the GAVI Alliance replenishment launch meeting in Brussels.
The freeze means that countries graduating from GAVI Alliance support will still be able to purchase GSK vaccines for the same price that GAVI pays for up to five years after the date of graduation. According to Witty, this will help avoid creating an economic dynamic in which national resources are overstretched as countries graduate.
Common Management Taxonomy: